Source: Medical Devices Business Review

Precision Biopsy: Precision Biopsy submits IDE application to FDA to expand clinical trial of ClariCore Biopsy system

Precision Biopsy announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for permission to enroll patients in the Transrectal Ultrasound (TRUS) and MR/Fusion arm of the company's study, expanding the scope of a clinical trial for its ClariCore Biopsy System in prostate cancer patients.

Read full article »

Top Competitors or Alternatives

Looks like nobody has added any competitors for Precision Biopsy yet.

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Amir Tehrani's photo - CEO of Precision Biopsy

CEO

Amir Tehrani

CEO Approval Rating

68/100

Precision Biopsy develops optical biopsy devices to improve the accuracy and reliability of prostate biopsies and the diagnosis of prostate cancer. Read more